| Title | Efficacy and safety of switching other tyrosine kinase inhibitors to regorafenib combined with primary PD-1 antibodies in patients with hepatocellular carcinoma |
| Author | |
| Publication Years | 2023-06-01
|
| ISSN | 0732-183X
|
| EISSN | 1527-7755
|
| Source Title | |
| Volume | 41
|
| Issue | 16
|
| Publication Place | TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
|
| Publisher | |
| SUSTech Authorship | Others
|
| Language | English
|
| URL | [Source Record] |
| Indexed By | |
| WOS Research Area | Oncology
|
| WOS Subject | Oncology
|
| WOS Accession No | WOS:001053772001700
|
| ESI Research Field | CLINICAL MEDICINE
|
| Data Source | Web of Science
|
| Citation statistics |
Cited Times [WOS]:0
|
| Document Type | Conference paper |
| Identifier | http://kc.sustech.edu.cn/handle/2SGJ60CL/571732 |
| Department | Department of Human Cell Biology and Genetics |
| Affiliation | 1.Capital Med Univ, Beijing, Peoples R China 2.Southern Univ Sci & Technol, Sch Med, Dept Human Cell Biol & Genet, Shenzhen, Peoples R China 3.Fifth Med Ctr PLA Gen Hosp, Dept Infect Dis, Beijing, Peoples R China |
| Recommended Citation GB/T 7714 |
Pan, Shida,Yu, Yingying,Wang, Siyu,et al. Efficacy and safety of switching other tyrosine kinase inhibitors to regorafenib combined with primary PD-1 antibodies in patients with hepatocellular carcinoma[C]. TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA:LIPPINCOTT WILLIAMS & WILKINS,2023.
|
| Files in This Item: | There are no files associated with this item. | |||||
Items in the repository are protected by copyright, with all rights reserved, unless otherwise indicated.
Edit Comment